NASDAQ:CVAC

CureVac Competitors

$110.78
-2.22 (-1.96 %)
(As of 04/20/2021 12:00 AM ET)
Add
Compare
Today's Range
$106.58
Now: $110.78
$111.27
50-Day Range
$79.79
MA: $91.20
$113.00
52-Week Range
$36.15
Now: $110.78
$151.80
Volume1.02 million shs
Average Volume870,394 shs
Market Capitalization$20.71 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

CureVac (NASDAQ:CVAC) Vs. ZTS, VRTX, REGN, TAK, ALXN, and BGNE

Should you be buying CVAC stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to CureVac, including Zoetis (ZTS), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Takeda Pharmaceutical (TAK), Alexion Pharmaceuticals (ALXN), and BeiGene (BGNE).

CureVac (NASDAQ:CVAC) and Zoetis (NYSE:ZTS) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings and profitability.

Profitability

This table compares CureVac and Zoetis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CureVacN/AN/AN/A
Zoetis25.50%63.89%14.99%

Earnings and Valuation

This table compares CureVac and Zoetis' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CureVacN/AN/AN/AN/AN/A
Zoetis$6.26 billion12.80$1.50 billion$3.6446.36

Zoetis has higher revenue and earnings than CureVac.

Insider and Institutional Ownership

4.3% of CureVac shares are owned by institutional investors. Comparatively, 92.5% of Zoetis shares are owned by institutional investors. 0.2% of Zoetis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and target prices for CureVac and Zoetis, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
CureVac11202.25
Zoetis06902.60

CureVac presently has a consensus target price of $58.3333, suggesting a potential downside of 47.34%. Zoetis has a consensus target price of $170.0833, suggesting a potential upside of 0.80%. Given Zoetis' stronger consensus rating and higher possible upside, analysts clearly believe Zoetis is more favorable than CureVac.

Summary

Zoetis beats CureVac on 9 of the 9 factors compared between the two stocks.

CureVac (NASDAQ:CVAC) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings and profitability.

Profitability

This table compares CureVac and Vertex Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CureVacN/AN/AN/A
Vertex Pharmaceuticals38.51%28.55%20.68%

Earnings and Valuation

This table compares CureVac and Vertex Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CureVacN/AN/AN/AN/AN/A
Vertex Pharmaceuticals$4.16 billion13.69$1.18 billion$4.2951.32

Vertex Pharmaceuticals has higher revenue and earnings than CureVac.

Insider and Institutional Ownership

4.3% of CureVac shares are owned by institutional investors. Comparatively, 92.2% of Vertex Pharmaceuticals shares are owned by institutional investors. 0.7% of Vertex Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and target prices for CureVac and Vertex Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
CureVac11202.25
Vertex Pharmaceuticals042112.88

CureVac presently has a consensus target price of $58.3333, suggesting a potential downside of 47.34%. Vertex Pharmaceuticals has a consensus target price of $293.2083, suggesting a potential upside of 33.18%. Given Vertex Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Vertex Pharmaceuticals is more favorable than CureVac.

Summary

Vertex Pharmaceuticals beats CureVac on 10 of the 10 factors compared between the two stocks.

CureVac (NASDAQ:CVAC) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings and profitability.

Profitability

This table compares CureVac and Regeneron Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CureVacN/AN/AN/A
Regeneron Pharmaceuticals38.28%28.97%20.11%

Earnings and Valuation

This table compares CureVac and Regeneron Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CureVacN/AN/AN/AN/AN/A
Regeneron Pharmaceuticals$7.86 billion6.87$2.12 billion$21.4723.49

Regeneron Pharmaceuticals has higher revenue and earnings than CureVac.

Insider and Institutional Ownership

4.3% of CureVac shares are owned by institutional investors. Comparatively, 85.0% of Regeneron Pharmaceuticals shares are owned by institutional investors. 11.8% of Regeneron Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and target prices for CureVac and Regeneron Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
CureVac11202.25
Regeneron Pharmaceuticals051412.80

CureVac presently has a consensus target price of $58.3333, suggesting a potential downside of 47.34%. Regeneron Pharmaceuticals has a consensus target price of $644.1739, suggesting a potential upside of 27.71%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Regeneron Pharmaceuticals is more favorable than CureVac.

Summary

Regeneron Pharmaceuticals beats CureVac on 10 of the 10 factors compared between the two stocks.

CureVac (NASDAQ:CVAC) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings and profitability.

Profitability

This table compares CureVac and Takeda Pharmaceutical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CureVacN/AN/AN/A
Takeda Pharmaceutical3.04%13.46%5.02%

Earnings and Valuation

This table compares CureVac and Takeda Pharmaceutical's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CureVacN/AN/AN/AN/AN/A
Takeda Pharmaceutical$30.20 billion1.76$407.02 million$1.789.46

Takeda Pharmaceutical has higher revenue and earnings than CureVac.

Insider and Institutional Ownership

4.3% of CureVac shares are owned by institutional investors. Comparatively, 3.4% of Takeda Pharmaceutical shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and target prices for CureVac and Takeda Pharmaceutical, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
CureVac11202.25
Takeda Pharmaceutical02002.00

CureVac presently has a consensus target price of $58.3333, suggesting a potential downside of 47.34%. Given CureVac's stronger consensus rating and higher possible upside, equities analysts clearly believe CureVac is more favorable than Takeda Pharmaceutical.

CureVac (NASDAQ:CVAC) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings and profitability.

Insider and Institutional Ownership

4.3% of CureVac shares are owned by institutional investors. Comparatively, 87.3% of Alexion Pharmaceuticals shares are owned by institutional investors. 4.0% of Alexion Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and target prices for CureVac and Alexion Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
CureVac11202.25
Alexion Pharmaceuticals017412.27

CureVac presently has a consensus target price of $58.3333, suggesting a potential downside of 47.34%. Alexion Pharmaceuticals has a consensus target price of $153.4286, suggesting a potential downside of 7.87%. Given Alexion Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Alexion Pharmaceuticals is more favorable than CureVac.

Profitability

This table compares CureVac and Alexion Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CureVacN/AN/AN/A
Alexion Pharmaceuticals16.32%23.16%14.76%

Earnings and Valuation

This table compares CureVac and Alexion Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CureVacN/AN/AN/AN/AN/A
Alexion Pharmaceuticals$4.99 billion7.37$2.40 billion$9.7417.10

Alexion Pharmaceuticals has higher revenue and earnings than CureVac.

Summary

Alexion Pharmaceuticals beats CureVac on 10 of the 10 factors compared between the two stocks.

BeiGene (NASDAQ:BGNE) and CureVac (NASDAQ:CVAC) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, valuation and risk.

Insider & Institutional Ownership

60.7% of BeiGene shares are held by institutional investors. Comparatively, 4.3% of CureVac shares are held by institutional investors. 9.0% of BeiGene shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of recent ratings and price targets for BeiGene and CureVac, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BeiGene21602.44
CureVac11202.25

BeiGene currently has a consensus target price of $319.3750, suggesting a potential upside of 9.09%. CureVac has a consensus target price of $58.3333, suggesting a potential downside of 47.34%. Given BeiGene's stronger consensus rating and higher possible upside, equities research analysts plainly believe BeiGene is more favorable than CureVac.

Profitability

This table compares BeiGene and CureVac's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BeiGene-569.22%-56.81%-39.93%
CureVacN/AN/AN/A

Earnings & Valuation

This table compares BeiGene and CureVac's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BeiGene$428.21 million62.69$-948,630,000.00($15.80)-18.53
CureVacN/AN/AN/AN/AN/A

CureVac has lower revenue, but higher earnings than BeiGene.

Summary

BeiGene beats CureVac on 6 of the 9 factors compared between the two stocks.


CureVac Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Zoetis logo
ZTS
Zoetis
2.2$168.74-0.5%$80.15 billion$6.26 billion50.07Increase in Short Interest
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.2$220.16-0.4%$56.98 billion$4.16 billion27.80Analyst Report
Analyst Revision
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
2.6$504.42-0.9%$54.04 billion$7.86 billion18.44Analyst Report
Takeda Pharmaceutical logo
TAK
Takeda Pharmaceutical
1.3$16.84-0.7%$53.14 billion$30.20 billion56.14Analyst Downgrade
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
1.7$166.54-0.6%$36.79 billion$4.99 billion38.91
BeiGene logo
BGNE
BeiGene
1.1$292.75-3.6%$26.85 billion$428.21 million-14.49
Royalty Pharma logo
RPRX
Royalty Pharma
1.9$41.44-0.8%$25.16 billionN/A0.00Dividend Announcement
Increase in Short Interest
Genmab A/S logo
GMAB
Genmab A/S
1.4$35.74-0.4%$23.44 billion$804.57 million27.71Analyst Report
News Coverage
Horizon Therapeutics Public logo
HZNP
Horizon Therapeutics Public
2.4$91.06-0.9%$20.40 billion$1.30 billion24.88
Catalent logo
CTLT
Catalent
1.7$109.36-0.7%$18.62 billion$3.09 billion69.66
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.8$136.03-1.0%$15.96 billion$219.75 million-17.37Analyst Report
Gap Up
Elanco Animal Health logo
ELAN
Elanco Animal Health
1.4$30.66-2.2%$14.50 billion$3.07 billion-53.79Analyst Report
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
2.1$79.45-0.2%$14.45 billion$1.70 billion18.18Analyst Report
Insider Selling
Zai Lab logo
ZLAB
Zai Lab
1.6$150.77-9.0%$13.36 billion$12.98 million-49.76Analyst Report
High Trading Volume
News Coverage
Gap Up
Grifols logo
GRFS
Grifols
1.3$18.20-1.1%$12.51 billion$5.71 billion16.25Analyst Report
Dr. Reddy's Laboratories logo
RDY
Dr. Reddy's Laboratories
1.3$67.36-2.0%$11.20 billion$2.32 billion55.67Gap Down
Teva Pharmaceutical Industries logo
TEVA
Teva Pharmaceutical Industries
1.6$10.11-1.7%$11.04 billion$16.89 billion-2.75Upcoming Earnings
Bausch Health Companies logo
BHC
Bausch Health Companies
1.9$28.44-2.4%$10.11 billion$8.60 billion-5.22
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
2.1$168.09-0.6%$9.47 billion$2.16 billion53.03Analyst Report
News Coverage
United Therapeutics logo
UTHR
United Therapeutics
1.5$207.58-1.8%$9.25 billion$1.45 billion19.64
Maravai LifeSciences logo
MRVI
Maravai LifeSciences
1.6$35.49-3.4%$9.14 billionN/A0.00Increase in Short Interest
BridgeBio Pharma logo
BBIO
BridgeBio Pharma
2.0N/AN/A$8.27 billion$40.56 million-15.87
Mirati Therapeutics logo
MRTX
Mirati Therapeutics
1.6$155.82-0.6%$7.89 billion$3.34 million-20.24
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.5$68.12-1.6%$7.07 billion$87.99 million-81.10
Ultragenyx Pharmaceutical logo
RARE
Ultragenyx Pharmaceutical
1.6$104.99-0.4%$7.03 billion$103.71 million-23.92Analyst Report
Insider Selling
GW Pharmaceuticals logo
GWPH
GW Pharmaceuticals
1.5$218.40-0.1%$6.85 billion$311.33 million-126.98News Coverage
Ascendis Pharma A/S logo
ASND
Ascendis Pharma A/S
1.5$125.03-2.7%$6.72 billion$14.98 million-15.23
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$41.16-3.0%$5.80 billion$1.12 billion85.75Analyst Report
Analyst Revision
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$71.30-1.4%$5.66 billion$380.83 million-9.12Analyst Report
TG Therapeutics logo
TGTX
TG Therapeutics
1.8$39.96-7.1%$5.62 billion$150,000.00-18.85Analyst Report
News Coverage
Perrigo logo
PRGO
Perrigo
2.3$42.05-0.8%$5.62 billion$4.84 billion-700.72Dividend Announcement
Allakos logo
ALLK
Allakos
1.7$104.13-1.0%$5.57 billionN/A-38.00
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$92.58-1.3%$5.37 billion$66.51 million17.08Analyst Report
Galapagos logo
GLPG
Galapagos
1.3$79.66-1.0%$5.22 billion$1.00 billion-12.07Analyst Report
Schrödinger logo
SDGR
Schrödinger
1.5$70.03-3.6%$4.90 billion$85.54 million0.00
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$73.65-1.8%$4.57 billionN/A-6.00Analyst Report
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$73.45-2.2%$4.29 billion$6.87 million-7.10Analyst Report
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$29.00-0.3%$4.22 billion$204.89 million-36.25
I-Mab logo
IMAB
I-Mab
1.2$56.82-2.2%$4.09 billion$4.31 million-1.97Gap Up
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$66.76-2.1%$4.03 billion$806.43 million-9.46Analyst Report
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.3$55.68-2.1%$3.89 billion$117.91 million-11.29
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$45.99-0.0%$3.70 billionN/A-6.20
LEGN
Legend Biotech
1.2$26.72-2.6%$3.55 billion$64.39 million0.00Analyst Report
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.2$65.62-3.4%$3.52 billion$1.11 billion21.10High Trading Volume
News Coverage
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$71.54-1.6%$3.50 billionN/A-20.38
Atea Pharmaceuticals logo
AVIR
Atea Pharmaceuticals
2.0$42.34-5.1%$3.50 billionN/A0.00Increase in Short Interest
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$18.81-0.1%$3.43 billion$114.62 million-7.58
Insmed logo
INSM
Insmed
1.2$32.30-0.2%$3.34 billion$136.47 million-12.42
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$20.80-0.4%$3.33 billion$339.08 million-12.09
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$46.31-2.7%$3.26 billion$306.98 million-6.63
This page was last updated on 4/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.